BUTYLBIGUANIDE CONCENTRATION IN PLASMA, LIVER, AND INTESTINE AFTER INTRAVENOUS AND ORAL-ADMINISTRATION TO MAN

被引：30

作者：

LINTZ, W

BERGER, W

AENISHAENSLIN, W

KUTOVA, V

BAERLOCHER, C

KAPP, JP

BECKMANN, R

机构：

[1] CHEM GRUNENTHAL GMBH, BIOCHEM ABT, D-519 STOLBERG, GERMANY

[2] UNIV BASEL, KANTONSPITAL, MED KLIN, BASEL, SWITZERLAND

来源：

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 1974年 / 7卷 / 06期

关键词：

D O I：

10.1007/BF00560356

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：433 / 448

页数：16

共 51 条

[1]

[Anonymous], 1971, ORAL WIRKSAME ANTIDI, DOI [DOI 10.1007/978-3-642-65265-3_8, 10.1007/978-3-642-65265-3_8]

[2] FATE OF BIGUANIDES IN MAN [J].

BECKMANN, R .

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1968, 148 (A3) :820-&

[3]

BECKMANN R, 1965, ARZNEI-FORSCHUNG, V15, P761

[4] EVALUATION OF A SUSTAINED RELEASE FORM OF ORAL ANTIDIABETIC BUTYLBIGUANIDE [J].

BECKMANN, R ;

LINTZ, W ;

SCHMIDTB.E .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1971, 3 (04) :221-&

[5]

BECKMANN R, 1965, ARZNEI-FORSCHUNG, V15, P765

[6]

BECKMANN R, 1966, ARCH INT PHARMACOD T, V160, P161

[7]

BECKMANN R, 1973, 3 INT DON S DIAB MEL, P189

[8]

BELLOMO A, 1972, Minerva Medica, V63, P291

[9]

Berger W, 1967, Ther Umsch, V24, P318

[10]

BERGER W, 1971, AKTUELLE PROBLEME AN, V16, P104

← 1 2 3 4 5 6 →